Vaccine News and Research

Latest Vaccine News and Research

HIV and syphilis on the rise among MSM

Rates of HIV and syphilis are very high and rising among men who have sex with men (MSM) in New York City, reports a study in the November issue of JAIDS: Journal of Acquired Immune Deficiency Syndromes. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

15 Nov 2011

New technology speeds up 'near real-time' vaccination data collection

New technology now makes it possible to collect 'near real-time' data about whether people are having any side effects from vaccination. By studying people who received the 2009-10 swine flu vaccination in Scotland, researchers showed that this rapid reporting can add another layer of safety to future vaccination campaigns. In addition, the data collected revealed no significant safety issues in patients exposed to the vaccine.

15 Nov 2011

Lentigen, UH Case Medical Center initiate LG631 Phase I trial in glioblastoma

University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection of hematopoietic stem cells (HSCs) from the dose limiting toxicity of chemotherapy with Temodar.

15 Nov 2011

Sinovac third quarter sales increase 60.8% to $15.4 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter financial results for the period ended September 30, 2011.

14 Nov 2011

Soligenix third quarter revenues increase to $5,796,000

Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the third quarter of 2011.

14 Nov 2011

Senior UK Parliamentarians visit Bangladesh to see full impact of pneumonia on children

To mark World Pneumonia Day, a senior UK parliamentary delegation travelled to Dhaka this week to see firsthand the full impact of pneumonia on Bangladeshi children.

14 Nov 2011

IVI receives WHO prequalification for new oral cholera vaccine

Shanchol-, a new oral cholera vaccine developed through the International Vaccine Institute (IVI), an international organization established by the United Nations and based in Seoul, recently received prequalification from the World Health Organization.

13 Nov 2011

Rapid expansion of global vaccine campaign against pneumonia 'unprecedented'

"A global push to bring a vaccine against the bacterial cause of pneumonia to communities that need it most is ramping up quickly, expanding to nearly 60 countries in the next five years," PBS NewsHour's "The Rundown" reports.

11 Nov 2011

Third annual World Pneumonia Day to be observed on Saturday

The third annual World Pneumonia Day will be observed on Saturday.

11 Nov 2011

Vaccination dramatically reduces incidence of Hib disease in young children

Vaccination against Haemophilus influenzae type b, or Hib, once the most common cause of bacterial meningitis in children, has dramatically reduced the incidence of Hib disease in young children over the past 20 years, according to a study published in Clinical Infectious Diseases and available online.

11 Nov 2011

Pharmaceutical industry should invest more in NTDs

In this Forbes opinion piece, contributor Sarika Bansal examines "what needs to happen for the pharmaceutical industry, academic researchers, and other key players to begin investing more seriously in" neglected tropical diseases.

11 Nov 2011

British researchers discover receptor necessary for malaria parasite to invade red blood cells, offering new vaccine hope

Researchers from the Wellcome Trust Sanger Institute in the U.K. have "made a critical discovery about the way the most deadly species of malaria parasite invades human red blood cells," Reuters reports.

11 Nov 2011

Universally effective malaria vaccine on the horizon

Scientists are excited with a new breakthrough in development of an effective vaccine against malaria. The latest study finds how malaria acts and how the vaccine would be able to protect individuals from malaria.

10 Nov 2011

DATATRAK third quarter revenue increases 13% to $2.1 million

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its operating results for the third quarter of 2011.

10 Nov 2011

POPG inhibits influenza infections in cell cultures and mouse models

A natural lipid in the fluid lining the lungs inhibits influenza infections in both cell cultures and mouse models, according to researchers at National Jewish Health. These findings, combined with previous studies demonstrating effectiveness against respiratory syncytial virus, suggest that the molecule, known as POPG, may have broad antiviral activity.

10 Nov 2011

Large-scale trials show HPV vaccine effective against multiple strains, could reduce need for screening

"Using GlaxoSmithKline's Cervarix vaccine to protect girls against the human papillomavirus (HPV) that causes cervical cancer is so effective that health authorities could reduce the need for later cervical screening," according to two studies published Wednesday in the journal Lancet Oncology, Reuters reports.

9 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.

9 Nov 2011

AMRI reports $50.2 million total revenue for third quarter 2011

...

9 Nov 2011

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Bristol-Myers Squibb Company today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events.

9 Nov 2011